Publications, Pharmaceutical

Using Bioequivalence and Particle Size Distribution to Develop OINDPs

The complexity of demonstrating bioequivalence in complex locally acting orally inhaled and nasal drug products is a barrier to the successful commercialization of generics.

This paper details a study to investigate the performance of a population bioequivalence (PBE) test based on particle size distribution measurements generated by morphologically directed Raman spectroscopy. Simulations of PBE trials were conducted across a range of median particle size and span values. Trial optimization strategies are presented based on the observed data and the general applicability of the approach is underlined. Appropriate trial design can help generic developers to avoid underpowered studies when using complex in vitro techniques to demonstrate bioequivalence.

Download Publication
6 Oct 2020

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

21 Apr 2020

Using in vitro dissolution tests for local bioequivalence in OINDPs

Webinars, Pharmaceutical, Innovation & Insights, Market Insights

Read More
1 Apr 2020

Demonstrating bioequivalence in generic orally inhaled drug products

Publications, Pharmaceutical, Innovation & Insights

Read More
1 Apr 2020

Patient training and onboarding for intranasal rescue treatments

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
1 Apr 2020

Is Now The Time to Shake up The pMDI Environment

Publications, Pharmaceutical, Sustainability, Innovation & Insights, Device Innovations, Product Solutions

Read More
1 … 30 31 32 33 34 35

Request Access

Close

Requesting access to Using Bioequivalence and Particle Size Distribution to Develop OINDPs.

  • This field is for validation purposes and should be left unchanged.

How Can We Help?

Back To Top